Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping

PHASE3UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 20, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Blood DiseaseBlood Transfusion, AutologousBlood DopingBlood Transfusion, Homologous
Interventions
BIOLOGICAL

Homologous Blood Transfusion

Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.

BIOLOGICAL

Autologous Blood Transfusion

Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.

Trial Locations (1)

Unknown

RECRUITING

Hamad Medical Corporation, Doha

Sponsors
All Listed Sponsors
collaborator

World Anti-Doping Agency

OTHER

collaborator

Anti-Doping Lab Qatar

UNKNOWN

collaborator

Sidra Medicine

OTHER

collaborator

Laboratorio Antidoping FMSI

UNKNOWN

lead

Hamad Medical Corporation

INDUSTRY

NCT03548766 - Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping | Biotech Hunter | Biotech Hunter